nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—CA2—esophageal cancer	0.735	1	CbGaD
Zoledronate—GGPS1—bronchus—esophageal cancer	0.0048	0.107	CbGeAlD
Zoledronate—GGPS1—trachea—esophageal cancer	0.00431	0.0962	CbGeAlD
Zoledronate—GGPS1—lung—esophageal cancer	0.0031	0.0691	CbGeAlD
Zoledronate—CA2—exocrine gland—esophageal cancer	0.00268	0.0598	CbGeAlD
Zoledronate—FDPS—bronchus—esophageal cancer	0.00221	0.0494	CbGeAlD
Zoledronate—FDPS—smooth muscle tissue—esophageal cancer	0.00217	0.0483	CbGeAlD
Zoledronate—GGPS1—lymph node—esophageal cancer	0.00212	0.0473	CbGeAlD
Zoledronate—CA12—trachea—esophageal cancer	0.00201	0.0448	CbGeAlD
Zoledronate—FDPS—trachea—esophageal cancer	0.00199	0.0443	CbGeAlD
Zoledronate—CA12—digestive system—esophageal cancer	0.00173	0.0386	CbGeAlD
Zoledronate—CA2—neck—esophageal cancer	0.00171	0.0383	CbGeAlD
Zoledronate—FDPS—digestive system—esophageal cancer	0.00171	0.0381	CbGeAlD
Zoledronate—CA12—lung—esophageal cancer	0.00144	0.0322	CbGeAlD
Zoledronate—FDPS—lung—esophageal cancer	0.00143	0.0319	CbGeAlD
Zoledronate—ABCC1—bronchus—esophageal cancer	0.00129	0.0287	CbGeAlD
Zoledronate—CA2—epithelium—esophageal cancer	0.00117	0.026	CbGeAlD
Zoledronate—ABCC1—trachea—esophageal cancer	0.00115	0.0257	CbGeAlD
Zoledronate—CA2—bronchus—esophageal cancer	0.00115	0.0256	CbGeAlD
Zoledronate—CA2—smooth muscle tissue—esophageal cancer	0.00112	0.0251	CbGeAlD
Zoledronate—CA2—trachea—esophageal cancer	0.00103	0.023	CbGeAlD
Zoledronate—FDPS—lymph node—esophageal cancer	0.000977	0.0218	CbGeAlD
Zoledronate—Risedronate—PTGS2—esophageal cancer	0.000909	0.529	CrCbGaD
Zoledronate—CA2—digestive system—esophageal cancer	0.000888	0.0198	CbGeAlD
Zoledronate—ABCC1—lung—esophageal cancer	0.000829	0.0185	CbGeAlD
Zoledronate—Clodronate—PTGS2—esophageal cancer	0.000811	0.471	CrCbGaD
Zoledronate—CA2—lung—esophageal cancer	0.000741	0.0165	CbGeAlD
Zoledronate—ABCC1—lymph node—esophageal cancer	0.000567	0.0127	CbGeAlD
Zoledronate—CA2—lymph node—esophageal cancer	0.000507	0.0113	CbGeAlD
Zoledronate—Sweating increased—Cisplatin—esophageal cancer	0.000461	0.00387	CcSEcCtD
Zoledronate—Bone disorder—Methotrexate—esophageal cancer	0.000458	0.00385	CcSEcCtD
Zoledronate—Swelling—Capecitabine—esophageal cancer	0.000458	0.00384	CcSEcCtD
Zoledronate—Abdominal discomfort—Cisplatin—esophageal cancer	0.000454	0.00381	CcSEcCtD
Zoledronate—Pancytopenia—Cisplatin—esophageal cancer	0.000449	0.00377	CcSEcCtD
Zoledronate—Eye pain—Capecitabine—esophageal cancer	0.000447	0.00375	CcSEcCtD
Zoledronate—Renal failure acute—Capecitabine—esophageal cancer	0.000437	0.00367	CcSEcCtD
Zoledronate—Inflammation—Methotrexate—esophageal cancer	0.000427	0.00358	CcSEcCtD
Zoledronate—Atrial fibrillation—Capecitabine—esophageal cancer	0.000426	0.00358	CcSEcCtD
Zoledronate—Renal impairment—Capecitabine—esophageal cancer	0.000424	0.00356	CcSEcCtD
Zoledronate—Thirst—Capecitabine—esophageal cancer	0.000424	0.00356	CcSEcCtD
Zoledronate—Arthritis—Capecitabine—esophageal cancer	0.000415	0.00349	CcSEcCtD
Zoledronate—Renal failure—Cisplatin—esophageal cancer	0.000415	0.00348	CcSEcCtD
Zoledronate—Lethargy—Capecitabine—esophageal cancer	0.000412	0.00346	CcSEcCtD
Zoledronate—Stomatitis—Cisplatin—esophageal cancer	0.000411	0.00345	CcSEcCtD
Zoledronate—Conjunctivitis—Cisplatin—esophageal cancer	0.00041	0.00344	CcSEcCtD
Zoledronate—Osteoarthritis—Capecitabine—esophageal cancer	0.000404	0.00339	CcSEcCtD
Zoledronate—Pain in extremity—Capecitabine—esophageal cancer	0.000404	0.00339	CcSEcCtD
Zoledronate—Bradycardia—Cisplatin—esophageal cancer	0.000386	0.00324	CcSEcCtD
Zoledronate—Blood creatinine increased—Capecitabine—esophageal cancer	0.000378	0.00317	CcSEcCtD
Zoledronate—Dehydration—Capecitabine—esophageal cancer	0.000375	0.00315	CcSEcCtD
Zoledronate—Neoplasm—Methotrexate—esophageal cancer	0.000374	0.00314	CcSEcCtD
Zoledronate—Urinary tract disorder—Cisplatin—esophageal cancer	0.000374	0.00314	CcSEcCtD
Zoledronate—Connective tissue disorder—Cisplatin—esophageal cancer	0.000372	0.00313	CcSEcCtD
Zoledronate—Urethral disorder—Cisplatin—esophageal cancer	0.000371	0.00312	CcSEcCtD
Zoledronate—Abdominal pain upper—Capecitabine—esophageal cancer	0.000369	0.00309	CcSEcCtD
Zoledronate—Hypokalaemia—Capecitabine—esophageal cancer	0.000367	0.00308	CcSEcCtD
Zoledronate—Nasopharyngitis—Capecitabine—esophageal cancer	0.000361	0.00303	CcSEcCtD
Zoledronate—Gastritis—Capecitabine—esophageal cancer	0.000357	0.003	CcSEcCtD
Zoledronate—Muscular weakness—Capecitabine—esophageal cancer	0.000356	0.00299	CcSEcCtD
Zoledronate—Eye disorder—Cisplatin—esophageal cancer	0.000354	0.00297	CcSEcCtD
Zoledronate—Cardiac disorder—Cisplatin—esophageal cancer	0.000352	0.00295	CcSEcCtD
Zoledronate—Flushing—Cisplatin—esophageal cancer	0.000352	0.00295	CcSEcCtD
Zoledronate—Abdominal distension—Capecitabine—esophageal cancer	0.000351	0.00295	CcSEcCtD
Zoledronate—Dysphagia—Capecitabine—esophageal cancer	0.000349	0.00293	CcSEcCtD
Zoledronate—Influenza—Capecitabine—esophageal cancer	0.000349	0.00293	CcSEcCtD
Zoledronate—Asthma—Capecitabine—esophageal cancer	0.000349	0.00293	CcSEcCtD
Zoledronate—Bronchospasm—Capecitabine—esophageal cancer	0.000343	0.00288	CcSEcCtD
Zoledronate—Immune system disorder—Cisplatin—esophageal cancer	0.000342	0.00287	CcSEcCtD
Zoledronate—Mediastinal disorder—Cisplatin—esophageal cancer	0.000341	0.00287	CcSEcCtD
Zoledronate—Sweating increased—Capecitabine—esophageal cancer	0.00034	0.00285	CcSEcCtD
Zoledronate—Arrhythmia—Cisplatin—esophageal cancer	0.000338	0.00284	CcSEcCtD
Zoledronate—Alopecia—Cisplatin—esophageal cancer	0.000335	0.00281	CcSEcCtD
Zoledronate—Abdominal discomfort—Capecitabine—esophageal cancer	0.000334	0.00281	CcSEcCtD
Zoledronate—Pancytopenia—Capecitabine—esophageal cancer	0.000331	0.00278	CcSEcCtD
Zoledronate—Erythema—Cisplatin—esophageal cancer	0.00033	0.00277	CcSEcCtD
Zoledronate—Malnutrition—Cisplatin—esophageal cancer	0.00033	0.00277	CcSEcCtD
Zoledronate—Neutropenia—Capecitabine—esophageal cancer	0.000326	0.00274	CcSEcCtD
Zoledronate—Renal failure acute—Methotrexate—esophageal cancer	0.000325	0.00273	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000324	0.00272	CcSEcCtD
Zoledronate—Weight increased—Capecitabine—esophageal cancer	0.000318	0.00267	CcSEcCtD
Zoledronate—Muscle spasms—Cisplatin—esophageal cancer	0.000317	0.00266	CcSEcCtD
Zoledronate—Weight decreased—Capecitabine—esophageal cancer	0.000316	0.00265	CcSEcCtD
Zoledronate—Infestation NOS—Capecitabine—esophageal cancer	0.000311	0.00261	CcSEcCtD
Zoledronate—Infestation—Capecitabine—esophageal cancer	0.000311	0.00261	CcSEcCtD
Zoledronate—Vision blurred—Cisplatin—esophageal cancer	0.000311	0.00261	CcSEcCtD
Zoledronate—Depression—Capecitabine—esophageal cancer	0.00031	0.0026	CcSEcCtD
Zoledronate—Tremor—Cisplatin—esophageal cancer	0.000309	0.00259	CcSEcCtD
Zoledronate—Lethargy—Methotrexate—esophageal cancer	0.000307	0.00257	CcSEcCtD
Zoledronate—Ill-defined disorder—Cisplatin—esophageal cancer	0.000306	0.00257	CcSEcCtD
Zoledronate—Renal failure—Capecitabine—esophageal cancer	0.000306	0.00257	CcSEcCtD
Zoledronate—Anaemia—Cisplatin—esophageal cancer	0.000305	0.00256	CcSEcCtD
Zoledronate—Stomatitis—Capecitabine—esophageal cancer	0.000303	0.00255	CcSEcCtD
Zoledronate—Conjunctivitis—Capecitabine—esophageal cancer	0.000302	0.00254	CcSEcCtD
Zoledronate—Urinary tract infection—Capecitabine—esophageal cancer	0.000302	0.00254	CcSEcCtD
Zoledronate—Osteoarthritis—Methotrexate—esophageal cancer	0.0003	0.00252	CcSEcCtD
Zoledronate—Malaise—Cisplatin—esophageal cancer	0.000297	0.0025	CcSEcCtD
Zoledronate—Haematuria—Capecitabine—esophageal cancer	0.000297	0.00249	CcSEcCtD
Zoledronate—Leukopenia—Cisplatin—esophageal cancer	0.000295	0.00248	CcSEcCtD
Zoledronate—Agranulocytosis—Capecitabine—esophageal cancer	0.00029	0.00244	CcSEcCtD
Zoledronate—Convulsion—Cisplatin—esophageal cancer	0.000286	0.0024	CcSEcCtD
Zoledronate—Bradycardia—Capecitabine—esophageal cancer	0.000284	0.00239	CcSEcCtD
Zoledronate—Myalgia—Cisplatin—esophageal cancer	0.000281	0.00236	CcSEcCtD
Zoledronate—Anxiety—Cisplatin—esophageal cancer	0.00028	0.00235	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000279	0.00234	CcSEcCtD
Zoledronate—Hypoaesthesia—Capecitabine—esophageal cancer	0.000278	0.00233	CcSEcCtD
Zoledronate—Discomfort—Cisplatin—esophageal cancer	0.000277	0.00233	CcSEcCtD
Zoledronate—Urinary tract disorder—Capecitabine—esophageal cancer	0.000276	0.00232	CcSEcCtD
Zoledronate—Oedema peripheral—Capecitabine—esophageal cancer	0.000275	0.00231	CcSEcCtD
Zoledronate—Connective tissue disorder—Capecitabine—esophageal cancer	0.000274	0.0023	CcSEcCtD
Zoledronate—Urethral disorder—Capecitabine—esophageal cancer	0.000274	0.0023	CcSEcCtD
Zoledronate—Anaphylactic shock—Cisplatin—esophageal cancer	0.000269	0.00226	CcSEcCtD
Zoledronate—Oedema—Cisplatin—esophageal cancer	0.000269	0.00226	CcSEcCtD
Zoledronate—Infection—Cisplatin—esophageal cancer	0.000267	0.00224	CcSEcCtD
Zoledronate—Nervous system disorder—Cisplatin—esophageal cancer	0.000264	0.00222	CcSEcCtD
Zoledronate—Thrombocytopenia—Cisplatin—esophageal cancer	0.000264	0.00221	CcSEcCtD
Zoledronate—Tachycardia—Cisplatin—esophageal cancer	0.000263	0.00221	CcSEcCtD
Zoledronate—Skin disorder—Cisplatin—esophageal cancer	0.000261	0.00219	CcSEcCtD
Zoledronate—Eye disorder—Capecitabine—esophageal cancer	0.000261	0.00219	CcSEcCtD
Zoledronate—Hyperhidrosis—Cisplatin—esophageal cancer	0.00026	0.00218	CcSEcCtD
Zoledronate—Asthma—Methotrexate—esophageal cancer	0.00026	0.00218	CcSEcCtD
Zoledronate—Cardiac disorder—Capecitabine—esophageal cancer	0.000259	0.00218	CcSEcCtD
Zoledronate—Flushing—Capecitabine—esophageal cancer	0.000259	0.00218	CcSEcCtD
Zoledronate—Anorexia—Cisplatin—esophageal cancer	0.000257	0.00215	CcSEcCtD
Zoledronate—CA14—Metabolism—SLC52A3—esophageal cancer	0.000256	0.00257	CbGpPWpGaD
Zoledronate—CA14—Metabolism—BLVRB—esophageal cancer	0.000256	0.00257	CbGpPWpGaD
Zoledronate—FDPS—SREBP signalling—PIK3CA—esophageal cancer	0.000255	0.00256	CbGpPWpGaD
Zoledronate—Angiopathy—Capecitabine—esophageal cancer	0.000253	0.00213	CcSEcCtD
Zoledronate—Immune system disorder—Capecitabine—esophageal cancer	0.000252	0.00212	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000252	0.00252	CbGpPWpGaD
Zoledronate—Mediastinal disorder—Capecitabine—esophageal cancer	0.000252	0.00211	CcSEcCtD
Zoledronate—Hypotension—Cisplatin—esophageal cancer	0.000251	0.00211	CcSEcCtD
Zoledronate—Chills—Capecitabine—esophageal cancer	0.000251	0.0021	CcSEcCtD
Zoledronate—GGPS1—Metabolism—GNG7—esophageal cancer	0.00025	0.00251	CbGpPWpGaD
Zoledronate—Arrhythmia—Capecitabine—esophageal cancer	0.000249	0.00209	CcSEcCtD
Zoledronate—Abdominal discomfort—Methotrexate—esophageal cancer	0.000249	0.00209	CcSEcCtD
Zoledronate—Alopecia—Capecitabine—esophageal cancer	0.000247	0.00207	CcSEcCtD
Zoledronate—Pancytopenia—Methotrexate—esophageal cancer	0.000247	0.00207	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000245	0.00206	CcSEcCtD
Zoledronate—Mental disorder—Capecitabine—esophageal cancer	0.000245	0.00205	CcSEcCtD
Zoledronate—Malnutrition—Capecitabine—esophageal cancer	0.000243	0.00204	CcSEcCtD
Zoledronate—Erythema—Capecitabine—esophageal cancer	0.000243	0.00204	CcSEcCtD
Zoledronate—Neutropenia—Methotrexate—esophageal cancer	0.000243	0.00204	CcSEcCtD
Zoledronate—Paraesthesia—Cisplatin—esophageal cancer	0.000242	0.00203	CcSEcCtD
Zoledronate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000241	0.00203	CcSEcCtD
Zoledronate—Dyspnoea—Cisplatin—esophageal cancer	0.00024	0.00201	CcSEcCtD
Zoledronate—Dysgeusia—Capecitabine—esophageal cancer	0.000238	0.002	CcSEcCtD
Zoledronate—Back pain—Capecitabine—esophageal cancer	0.000235	0.00197	CcSEcCtD
Zoledronate—GGPS1—Metabolism—ALDH2—esophageal cancer	0.000234	0.00235	CbGpPWpGaD
Zoledronate—Decreased appetite—Cisplatin—esophageal cancer	0.000234	0.00196	CcSEcCtD
Zoledronate—Muscle spasms—Capecitabine—esophageal cancer	0.000234	0.00196	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000232	0.00195	CcSEcCtD
Zoledronate—Infestation NOS—Methotrexate—esophageal cancer	0.000232	0.00194	CcSEcCtD
Zoledronate—Infestation—Methotrexate—esophageal cancer	0.000232	0.00194	CcSEcCtD
Zoledronate—Depression—Methotrexate—esophageal cancer	0.000231	0.00194	CcSEcCtD
Zoledronate—Pain—Cisplatin—esophageal cancer	0.00023	0.00193	CcSEcCtD
Zoledronate—Vision blurred—Capecitabine—esophageal cancer	0.000229	0.00192	CcSEcCtD
Zoledronate—Tremor—Capecitabine—esophageal cancer	0.000228	0.00191	CcSEcCtD
Zoledronate—Renal failure—Methotrexate—esophageal cancer	0.000228	0.00191	CcSEcCtD
Zoledronate—Stomatitis—Methotrexate—esophageal cancer	0.000226	0.00189	CcSEcCtD
Zoledronate—Ill-defined disorder—Capecitabine—esophageal cancer	0.000226	0.00189	CcSEcCtD
Zoledronate—Conjunctivitis—Methotrexate—esophageal cancer	0.000225	0.00189	CcSEcCtD
Zoledronate—Anaemia—Capecitabine—esophageal cancer	0.000225	0.00189	CcSEcCtD
Zoledronate—FDPS—Metabolism—SLC52A3—esophageal cancer	0.000224	0.00224	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—BLVRB—esophageal cancer	0.000224	0.00224	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GSTT1—esophageal cancer	0.000223	0.00223	CbGpPWpGaD
Zoledronate—Feeling abnormal—Cisplatin—esophageal cancer	0.000222	0.00186	CcSEcCtD
Zoledronate—Haematuria—Methotrexate—esophageal cancer	0.000221	0.00185	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CYP2A6—esophageal cancer	0.00022	0.00221	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000219	0.0022	CbGpPWpGaD
Zoledronate—Malaise—Capecitabine—esophageal cancer	0.000219	0.00184	CcSEcCtD
Zoledronate—Vertigo—Capecitabine—esophageal cancer	0.000218	0.00183	CcSEcCtD
Zoledronate—Syncope—Capecitabine—esophageal cancer	0.000218	0.00183	CcSEcCtD
Zoledronate—CA14—Metabolism—SLC10A2—esophageal cancer	0.000218	0.00218	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CA1—esophageal cancer	0.000218	0.00218	CbGpPWpGaD
Zoledronate—Leukopenia—Capecitabine—esophageal cancer	0.000218	0.00183	CcSEcCtD
Zoledronate—Agranulocytosis—Methotrexate—esophageal cancer	0.000216	0.00181	CcSEcCtD
Zoledronate—CA12—Metabolism—SLC52A3—esophageal cancer	0.000216	0.00216	CbGpPWpGaD
Zoledronate—CA12—Metabolism—BLVRB—esophageal cancer	0.000216	0.00216	CbGpPWpGaD
Zoledronate—Palpitations—Capecitabine—esophageal cancer	0.000215	0.0018	CcSEcCtD
Zoledronate—Loss of consciousness—Capecitabine—esophageal cancer	0.000214	0.00179	CcSEcCtD
Zoledronate—Body temperature increased—Cisplatin—esophageal cancer	0.000213	0.00179	CcSEcCtD
Zoledronate—Cough—Capecitabine—esophageal cancer	0.000212	0.00178	CcSEcCtD
Zoledronate—Hypertension—Capecitabine—esophageal cancer	0.00021	0.00176	CcSEcCtD
Zoledronate—GGPS1—Metabolism—PTGS1—esophageal cancer	0.000209	0.00209	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—ENO1—esophageal cancer	0.000209	0.00209	CbGpPWpGaD
Zoledronate—Chest pain—Capecitabine—esophageal cancer	0.000207	0.00174	CcSEcCtD
Zoledronate—Arthralgia—Capecitabine—esophageal cancer	0.000207	0.00174	CcSEcCtD
Zoledronate—Myalgia—Capecitabine—esophageal cancer	0.000207	0.00174	CcSEcCtD
Zoledronate—Anxiety—Capecitabine—esophageal cancer	0.000206	0.00173	CcSEcCtD
Zoledronate—GGPS1—Metabolism—PSME1—esophageal cancer	0.000206	0.00206	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PSME2—esophageal cancer	0.000206	0.00206	CbGpPWpGaD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000206	0.00173	CcSEcCtD
Zoledronate—Urinary tract disorder—Methotrexate—esophageal cancer	0.000205	0.00172	CcSEcCtD
Zoledronate—Discomfort—Capecitabine—esophageal cancer	0.000204	0.00172	CcSEcCtD
Zoledronate—Urethral disorder—Methotrexate—esophageal cancer	0.000204	0.00171	CcSEcCtD
Zoledronate—Dry mouth—Capecitabine—esophageal cancer	0.000202	0.0017	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.0002	0.00201	CbGpPWpGaD
Zoledronate—Confusional state—Capecitabine—esophageal cancer	0.0002	0.00168	CcSEcCtD
Zoledronate—CA14—Metabolism—CA2—esophageal cancer	0.000199	0.002	CbGpPWpGaD
Zoledronate—Oedema—Capecitabine—esophageal cancer	0.000198	0.00167	CcSEcCtD
Zoledronate—Hypersensitivity—Cisplatin—esophageal cancer	0.000198	0.00166	CcSEcCtD
Zoledronate—Infection—Capecitabine—esophageal cancer	0.000197	0.00165	CcSEcCtD
Zoledronate—Shock—Capecitabine—esophageal cancer	0.000195	0.00164	CcSEcCtD
Zoledronate—Nervous system disorder—Capecitabine—esophageal cancer	0.000195	0.00163	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—esophageal cancer	0.000194	0.00163	CcSEcCtD
Zoledronate—Thrombocytopenia—Capecitabine—esophageal cancer	0.000194	0.00163	CcSEcCtD
Zoledronate—Tachycardia—Capecitabine—esophageal cancer	0.000194	0.00163	CcSEcCtD
Zoledronate—Asthenia—Cisplatin—esophageal cancer	0.000193	0.00162	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—esophageal cancer	0.000193	0.00162	CcSEcCtD
Zoledronate—Skin disorder—Capecitabine—esophageal cancer	0.000193	0.00162	CcSEcCtD
Zoledronate—Hyperhidrosis—Capecitabine—esophageal cancer	0.000192	0.00161	CcSEcCtD
Zoledronate—ABCC1—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000192	0.00192	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CA1—esophageal cancer	0.00019	0.00191	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—SLC10A2—esophageal cancer	0.00019	0.00191	CbGpPWpGaD
Zoledronate—Anorexia—Capecitabine—esophageal cancer	0.000189	0.00159	CcSEcCtD
Zoledronate—Angiopathy—Methotrexate—esophageal cancer	0.000189	0.00158	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—esophageal cancer	0.000188	0.00158	CcSEcCtD
Zoledronate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000187	0.00157	CcSEcCtD
Zoledronate—Chills—Methotrexate—esophageal cancer	0.000187	0.00157	CcSEcCtD
Zoledronate—Hypotension—Capecitabine—esophageal cancer	0.000185	0.00156	CcSEcCtD
Zoledronate—CA14—Metabolism—ADH7—esophageal cancer	0.000185	0.00186	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PLCE1—esophageal cancer	0.000185	0.00186	CbGpPWpGaD
Zoledronate—Diarrhoea—Cisplatin—esophageal cancer	0.000184	0.00155	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—esophageal cancer	0.000184	0.00154	CcSEcCtD
Zoledronate—CA12—Metabolism—CA1—esophageal cancer	0.000184	0.00184	CbGpPWpGaD
Zoledronate—CA12—Metabolism—SLC10A2—esophageal cancer	0.000184	0.00184	CbGpPWpGaD
Zoledronate—Mental disorder—Methotrexate—esophageal cancer	0.000182	0.00153	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—esophageal cancer	0.000181	0.00152	CcSEcCtD
Zoledronate—Erythema—Methotrexate—esophageal cancer	0.000181	0.00152	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000181	0.00152	CcSEcCtD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.00018	0.0018	CbGpPWpGaD
Zoledronate—Insomnia—Capecitabine—esophageal cancer	0.000179	0.00151	CcSEcCtD
Zoledronate—Paraesthesia—Capecitabine—esophageal cancer	0.000178	0.0015	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CYP1B1—esophageal cancer	0.000178	0.00178	CbGpPWpGaD
Zoledronate—Dysgeusia—Methotrexate—esophageal cancer	0.000177	0.00149	CcSEcCtD
Zoledronate—Dyspnoea—Capecitabine—esophageal cancer	0.000177	0.00148	CcSEcCtD
Zoledronate—Back pain—Methotrexate—esophageal cancer	0.000175	0.00147	CcSEcCtD
Zoledronate—Dyspepsia—Capecitabine—esophageal cancer	0.000175	0.00147	CcSEcCtD
Zoledronate—FDPS—Metabolism—CA2—esophageal cancer	0.000174	0.00174	CbGpPWpGaD
Zoledronate—Decreased appetite—Capecitabine—esophageal cancer	0.000172	0.00145	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000171	0.00144	CcSEcCtD
Zoledronate—Vomiting—Cisplatin—esophageal cancer	0.000171	0.00144	CcSEcCtD
Zoledronate—Fatigue—Capecitabine—esophageal cancer	0.000171	0.00144	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—esophageal cancer	0.000171	0.00143	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.00017	0.00171	CbGpPWpGaD
Zoledronate—Rash—Cisplatin—esophageal cancer	0.00017	0.00142	CcSEcCtD
Zoledronate—Constipation—Capecitabine—esophageal cancer	0.00017	0.00142	CcSEcCtD
Zoledronate—Pain—Capecitabine—esophageal cancer	0.00017	0.00142	CcSEcCtD
Zoledronate—Dermatitis—Cisplatin—esophageal cancer	0.00017	0.00142	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—esophageal cancer	0.000168	0.00141	CcSEcCtD
Zoledronate—CA12—Metabolism—CA2—esophageal cancer	0.000168	0.00168	CbGpPWpGaD
Zoledronate—Anaemia—Methotrexate—esophageal cancer	0.000167	0.0014	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CYP19A1—esophageal cancer	0.000167	0.00167	CbGpPWpGaD
Zoledronate—CA2—Metabolism—SLC52A3—esophageal cancer	0.000165	0.00165	CbGpPWpGaD
Zoledronate—CA2—Metabolism—BLVRB—esophageal cancer	0.000165	0.00165	CbGpPWpGaD
Zoledronate—Feeling abnormal—Capecitabine—esophageal cancer	0.000163	0.00137	CcSEcCtD
Zoledronate—Malaise—Methotrexate—esophageal cancer	0.000163	0.00137	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—esophageal cancer	0.000163	0.00136	CcSEcCtD
Zoledronate—CA14—Metabolism—ADH1B—esophageal cancer	0.000162	0.00163	CbGpPWpGaD
Zoledronate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000162	0.00136	CcSEcCtD
Zoledronate—Leukopenia—Methotrexate—esophageal cancer	0.000162	0.00136	CcSEcCtD
Zoledronate—FDPS—Metabolism—PLCE1—esophageal cancer	0.000162	0.00162	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—ADH7—esophageal cancer	0.000162	0.00162	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.00016	0.0016	CbGpPWpGaD
Zoledronate—Nausea—Cisplatin—esophageal cancer	0.00016	0.00134	CcSEcCtD
Zoledronate—Cough—Methotrexate—esophageal cancer	0.000158	0.00133	CcSEcCtD
Zoledronate—Urticaria—Capecitabine—esophageal cancer	0.000158	0.00132	CcSEcCtD
Zoledronate—Body temperature increased—Capecitabine—esophageal cancer	0.000157	0.00132	CcSEcCtD
Zoledronate—Abdominal pain—Capecitabine—esophageal cancer	0.000157	0.00132	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—esophageal cancer	0.000157	0.00132	CcSEcCtD
Zoledronate—CA12—Metabolism—ADH7—esophageal cancer	0.000156	0.00156	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PLCE1—esophageal cancer	0.000156	0.00156	CbGpPWpGaD
Zoledronate—CA14—Metabolism—TYMP—esophageal cancer	0.000155	0.00156	CbGpPWpGaD
Zoledronate—Chest pain—Methotrexate—esophageal cancer	0.000154	0.00129	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—esophageal cancer	0.000154	0.00129	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—esophageal cancer	0.000154	0.00129	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000153	0.00128	CcSEcCtD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000153	0.00153	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—HMOX1—esophageal cancer	0.000152	0.00153	CbGpPWpGaD
Zoledronate—Discomfort—Methotrexate—esophageal cancer	0.000152	0.00128	CcSEcCtD
Zoledronate—CA14—Metabolism—CYP26A1—esophageal cancer	0.000151	0.00151	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000149	0.0015	CbGpPWpGaD
Zoledronate—Confusional state—Methotrexate—esophageal cancer	0.000149	0.00125	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—esophageal cancer	0.000148	0.00124	CcSEcCtD
Zoledronate—CA14—Metabolism—ALOX15—esophageal cancer	0.000147	0.00147	CbGpPWpGaD
Zoledronate—Infection—Methotrexate—esophageal cancer	0.000147	0.00123	CcSEcCtD
Zoledronate—GGPS1—Metabolism—ABCB1—esophageal cancer	0.000146	0.00147	CbGpPWpGaD
Zoledronate—Hypersensitivity—Capecitabine—esophageal cancer	0.000146	0.00123	CcSEcCtD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000145	0.00145	CbGpPWpGaD
Zoledronate—Nervous system disorder—Methotrexate—esophageal cancer	0.000145	0.00122	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000145	0.00121	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—esophageal cancer	0.000143	0.0012	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000143	0.0012	CcSEcCtD
Zoledronate—Asthenia—Capecitabine—esophageal cancer	0.000142	0.00119	CcSEcCtD
Zoledronate—FDPS—Metabolism—ADH1B—esophageal cancer	0.000142	0.00142	CbGpPWpGaD
Zoledronate—Anorexia—Methotrexate—esophageal cancer	0.000141	0.00118	CcSEcCtD
Zoledronate—Pruritus—Capecitabine—esophageal cancer	0.00014	0.00118	CcSEcCtD
Zoledronate—CA2—Metabolism—SLC10A2—esophageal cancer	0.00014	0.00141	CbGpPWpGaD
Zoledronate—CA14—Metabolism—TPI1—esophageal cancer	0.00014	0.00141	CbGpPWpGaD
Zoledronate—CA14—Metabolism—GSTO1—esophageal cancer	0.00014	0.00141	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CA1—esophageal cancer	0.00014	0.00141	CbGpPWpGaD
Zoledronate—Hypotension—Methotrexate—esophageal cancer	0.000138	0.00116	CcSEcCtD
Zoledronate—CA12—Metabolism—ADH1B—esophageal cancer	0.000137	0.00137	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000136	0.00137	CbGpPWpGaD
Zoledronate—Diarrhoea—Capecitabine—esophageal cancer	0.000136	0.00114	CcSEcCtD
Zoledronate—FDPS—Metabolism—TYMP—esophageal cancer	0.000136	0.00136	CbGpPWpGaD
Zoledronate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000135	0.00113	CcSEcCtD
Zoledronate—CA14—Metabolism—ALDOB—esophageal cancer	0.000135	0.00135	CbGpPWpGaD
Zoledronate—Insomnia—Methotrexate—esophageal cancer	0.000134	0.00112	CcSEcCtD
Zoledronate—Paraesthesia—Methotrexate—esophageal cancer	0.000133	0.00111	CcSEcCtD
Zoledronate—FDPS—Metabolism—CYP26A1—esophageal cancer	0.000132	0.00132	CbGpPWpGaD
Zoledronate—Dyspnoea—Methotrexate—esophageal cancer	0.000132	0.00111	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—esophageal cancer	0.000131	0.0011	CcSEcCtD
Zoledronate—Dizziness—Capecitabine—esophageal cancer	0.000131	0.0011	CcSEcCtD
Zoledronate—CA12—Metabolism—TYMP—esophageal cancer	0.000131	0.00131	CbGpPWpGaD
Zoledronate—Dyspepsia—Methotrexate—esophageal cancer	0.00013	0.00109	CcSEcCtD
Zoledronate—CA14—Metabolism—GAPDH—esophageal cancer	0.00013	0.0013	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000129	0.0013	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—ALOX15—esophageal cancer	0.000129	0.00129	CbGpPWpGaD
Zoledronate—Decreased appetite—Methotrexate—esophageal cancer	0.000128	0.00108	CcSEcCtD
Zoledronate—CA14—Metabolism—CRABP1—esophageal cancer	0.000128	0.00129	CbGpPWpGaD
Zoledronate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000128	0.00107	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—esophageal cancer	0.000127	0.00107	CcSEcCtD
Zoledronate—CA12—Metabolism—CYP26A1—esophageal cancer	0.000127	0.00128	CbGpPWpGaD
Zoledronate—Pain—Methotrexate—esophageal cancer	0.000126	0.00106	CcSEcCtD
Zoledronate—Vomiting—Capecitabine—esophageal cancer	0.000126	0.00106	CcSEcCtD
Zoledronate—Rash—Capecitabine—esophageal cancer	0.000125	0.00105	CcSEcCtD
Zoledronate—Dermatitis—Capecitabine—esophageal cancer	0.000125	0.00105	CcSEcCtD
Zoledronate—Headache—Capecitabine—esophageal cancer	0.000124	0.00104	CcSEcCtD
Zoledronate—CA12—Metabolism—ALOX15—esophageal cancer	0.000124	0.00124	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000123	0.00124	CbGpPWpGaD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—esophageal cancer	0.000123	0.00123	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—TPI1—esophageal cancer	0.000123	0.00123	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GSTO1—esophageal cancer	0.000123	0.00123	CbGpPWpGaD
Zoledronate—CA14—Metabolism—GNG7—esophageal cancer	0.000122	0.00122	CbGpPWpGaD
Zoledronate—Feeling abnormal—Methotrexate—esophageal cancer	0.000122	0.00102	CcSEcCtD
Zoledronate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000121	0.00101	CcSEcCtD
Zoledronate—CA2—Metabolism—PLCE1—esophageal cancer	0.000119	0.0012	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ADH7—esophageal cancer	0.000119	0.0012	CbGpPWpGaD
Zoledronate—CA12—Metabolism—TPI1—esophageal cancer	0.000118	0.00119	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GSTO1—esophageal cancer	0.000118	0.00119	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000118	0.00119	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000118	0.00119	CbGpPWpGaD
Zoledronate—Nausea—Capecitabine—esophageal cancer	0.000118	0.000989	CcSEcCtD
Zoledronate—FDPS—Metabolism—ALDOB—esophageal cancer	0.000118	0.00118	CbGpPWpGaD
Zoledronate—Urticaria—Methotrexate—esophageal cancer	0.000117	0.000985	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—esophageal cancer	0.000117	0.00098	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—esophageal cancer	0.000117	0.00098	CcSEcCtD
Zoledronate—CA14—Metabolism—ALDH2—esophageal cancer	0.000114	0.00115	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ALDOB—esophageal cancer	0.000113	0.00114	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GAPDH—esophageal cancer	0.000113	0.00113	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CRABP1—esophageal cancer	0.000112	0.00112	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000111	0.00111	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GAPDH—esophageal cancer	0.000109	0.00109	CbGpPWpGaD
Zoledronate—CA14—Metabolism—GSTT1—esophageal cancer	0.000109	0.00109	CbGpPWpGaD
Zoledronate—Hypersensitivity—Methotrexate—esophageal cancer	0.000109	0.000913	CcSEcCtD
Zoledronate—CA12—Metabolism—CRABP1—esophageal cancer	0.000108	0.00108	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CYP2A6—esophageal cancer	0.000108	0.00108	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GNG7—esophageal cancer	0.000107	0.00107	CbGpPWpGaD
Zoledronate—Asthenia—Methotrexate—esophageal cancer	0.000106	0.00089	CcSEcCtD
Zoledronate—CA2—Metabolism—ADH1B—esophageal cancer	0.000105	0.00105	CbGpPWpGaD
Zoledronate—Pruritus—Methotrexate—esophageal cancer	0.000104	0.000877	CcSEcCtD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000103	0.00103	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GNG7—esophageal cancer	0.000103	0.00103	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTGS1—esophageal cancer	0.000102	0.00102	CbGpPWpGaD
Zoledronate—CA14—Metabolism—ENO1—esophageal cancer	0.000102	0.00102	CbGpPWpGaD
Zoledronate—Diarrhoea—Methotrexate—esophageal cancer	0.000101	0.000848	CcSEcCtD
Zoledronate—CA14—Metabolism—PSME1—esophageal cancer	0.0001	0.00101	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PSME2—esophageal cancer	0.0001	0.00101	CbGpPWpGaD
Zoledronate—CA2—Metabolism—TYMP—esophageal cancer	0.0001	0.001	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—ALDH2—esophageal cancer	0.0001	0.001	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—CREBBP—esophageal cancer	9.77e-05	0.000979	CbGpPWpGaD
Zoledronate—Dizziness—Methotrexate—esophageal cancer	9.77e-05	0.00082	CcSEcCtD
Zoledronate—CA2—Metabolism—CYP26A1—esophageal cancer	9.73e-05	0.000975	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ALDH2—esophageal cancer	9.64e-05	0.000966	CbGpPWpGaD
Zoledronate—ABCC1—Disease—SLC52A3—esophageal cancer	9.54e-05	0.000956	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GSTT1—esophageal cancer	9.51e-05	0.000953	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ALOX15—esophageal cancer	9.48e-05	0.00095	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CYP2A6—esophageal cancer	9.4e-05	0.000942	CbGpPWpGaD
Zoledronate—Vomiting—Methotrexate—esophageal cancer	9.39e-05	0.000788	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.37e-05	0.000939	CbGpPWpGaD
Zoledronate—Rash—Methotrexate—esophageal cancer	9.31e-05	0.000782	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—esophageal cancer	9.3e-05	0.000781	CcSEcCtD
Zoledronate—Headache—Methotrexate—esophageal cancer	9.25e-05	0.000777	CcSEcCtD
Zoledronate—CA12—Metabolism—GSTT1—esophageal cancer	9.17e-05	0.000919	CbGpPWpGaD
Zoledronate—ABCC1—Disease—KMT2D—esophageal cancer	9.1e-05	0.000912	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CYP2A6—esophageal cancer	9.07e-05	0.000909	CbGpPWpGaD
Zoledronate—CA2—Metabolism—TPI1—esophageal cancer	9.04e-05	0.000906	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GSTO1—esophageal cancer	9.04e-05	0.000906	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.99e-05	0.000901	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	8.96e-05	0.000898	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—ENO1—esophageal cancer	8.91e-05	0.000893	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTGS1—esophageal cancer	8.91e-05	0.000893	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PSME2—esophageal cancer	8.78e-05	0.00088	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PSME1—esophageal cancer	8.78e-05	0.00088	CbGpPWpGaD
Zoledronate—Nausea—Methotrexate—esophageal cancer	8.77e-05	0.000736	CcSEcCtD
Zoledronate—GGPS1—Metabolism—NOS3—esophageal cancer	8.75e-05	0.000877	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CYP1B1—esophageal cancer	8.67e-05	0.000869	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ALDOB—esophageal cancer	8.67e-05	0.000869	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ENO1—esophageal cancer	8.59e-05	0.000861	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTGS1—esophageal cancer	8.59e-05	0.000861	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PSME2—esophageal cancer	8.47e-05	0.000849	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PSME1—esophageal cancer	8.47e-05	0.000849	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GAPDH—esophageal cancer	8.35e-05	0.000836	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CRABP1—esophageal cancer	8.27e-05	0.000829	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CYP19A1—esophageal cancer	8.15e-05	0.000817	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—GNG7—esophageal cancer	8.13e-05	0.000815	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PTGS2—esophageal cancer	8e-05	0.000802	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—BLVRB—esophageal cancer	7.99e-05	0.000801	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—SLC52A3—esophageal cancer	7.99e-05	0.000801	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GNG7—esophageal cancer	7.87e-05	0.000788	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.67e-05	0.000769	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CYP1B1—esophageal cancer	7.58e-05	0.000759	CbGpPWpGaD
Zoledronate—CA14—Metabolism—HMOX1—esophageal cancer	7.44e-05	0.000745	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ALDH2—esophageal cancer	7.37e-05	0.000739	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CYP1B1—esophageal cancer	7.31e-05	0.000732	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	7.14e-05	0.000716	CbGpPWpGaD
Zoledronate—CA14—Metabolism—ABCB1—esophageal cancer	7.14e-05	0.000716	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CYP19A1—esophageal cancer	7.13e-05	0.000714	CbGpPWpGaD
Zoledronate—ABCC1—Disease—FKBP1A—esophageal cancer	7.06e-05	0.000707	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GSTT1—esophageal cancer	7.01e-05	0.000703	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CYP2A6—esophageal cancer	6.93e-05	0.000695	CbGpPWpGaD
Zoledronate—ABCC1—Disease—DOCK2—esophageal cancer	6.9e-05	0.000691	CbGpPWpGaD
Zoledronate—ABCC1—Disease—WIF1—esophageal cancer	6.9e-05	0.000691	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CYP19A1—esophageal cancer	6.87e-05	0.000689	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CA1—esophageal cancer	6.79e-05	0.000681	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—SLC10A2—esophageal cancer	6.79e-05	0.000681	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—EP300—esophageal cancer	6.66e-05	0.000667	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTGS1—esophageal cancer	6.57e-05	0.000659	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ENO1—esophageal cancer	6.57e-05	0.000659	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—HMOX1—esophageal cancer	6.5e-05	0.000652	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PSME1—esophageal cancer	6.48e-05	0.000649	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PSME2—esophageal cancer	6.48e-05	0.000649	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.38e-05	0.000639	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CSNK1A1—esophageal cancer	6.37e-05	0.000638	CbGpPWpGaD
Zoledronate—CA12—Metabolism—HMOX1—esophageal cancer	6.27e-05	0.000628	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—ABCB1—esophageal cancer	6.24e-05	0.000625	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CA2—esophageal cancer	6.21e-05	0.000623	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	6.07e-05	0.000609	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ABCB1—esophageal cancer	6.02e-05	0.000603	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PLCE1—esophageal cancer	5.78e-05	0.000579	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ADH7—esophageal cancer	5.78e-05	0.000579	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.71e-05	0.000572	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CYP1B1—esophageal cancer	5.59e-05	0.00056	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ELMO1—esophageal cancer	5.35e-05	0.000536	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CYP19A1—esophageal cancer	5.25e-05	0.000526	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TPI1—esophageal cancer	5.23e-05	0.000524	CbGpPWpGaD
Zoledronate—ABCC1—Disease—GSTO1—esophageal cancer	5.23e-05	0.000524	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ADH1B—esophageal cancer	5.07e-05	0.000508	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ALDOB—esophageal cancer	5.01e-05	0.000502	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.95e-05	0.000497	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PIK3CA—esophageal cancer	4.92e-05	0.000493	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—TYMP—esophageal cancer	4.84e-05	0.000485	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HIST1H2BM—esophageal cancer	4.82e-05	0.000483	CbGpPWpGaD
Zoledronate—ABCC1—Disease—GAPDH—esophageal cancer	4.82e-05	0.000483	CbGpPWpGaD
Zoledronate—CA2—Metabolism—HMOX1—esophageal cancer	4.79e-05	0.00048	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CREBBP—esophageal cancer	4.77e-05	0.000478	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	4.76e-05	0.000477	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.72e-05	0.000473	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CYP26A1—esophageal cancer	4.71e-05	0.000472	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ABCB1—esophageal cancer	4.6e-05	0.000461	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ALOX15—esophageal cancer	4.59e-05	0.00046	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GSTO1—esophageal cancer	4.38e-05	0.000439	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—TPI1—esophageal cancer	4.38e-05	0.000439	CbGpPWpGaD
Zoledronate—CA14—Metabolism—NOS3—esophageal cancer	4.27e-05	0.000428	CbGpPWpGaD
Zoledronate—ABCC1—Disease—XIAP—esophageal cancer	4.26e-05	0.000427	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ALDOB—esophageal cancer	4.2e-05	0.000421	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CREBBP—esophageal cancer	4.17e-05	0.000418	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GAPDH—esophageal cancer	4.04e-05	0.000405	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CREBBP—esophageal cancer	4.02e-05	0.000403	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CRABP1—esophageal cancer	4e-05	0.000401	CbGpPWpGaD
Zoledronate—ABCC1—Disease—B2M—esophageal cancer	3.96e-05	0.000397	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTGS2—esophageal cancer	3.91e-05	0.000392	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GNG7—esophageal cancer	3.81e-05	0.000382	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ENO1—esophageal cancer	3.8e-05	0.000381	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PSME2—esophageal cancer	3.74e-05	0.000375	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PSME1—esophageal cancer	3.74e-05	0.000375	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—NOS3—esophageal cancer	3.73e-05	0.000374	CbGpPWpGaD
Zoledronate—CA12—Metabolism—NOS3—esophageal cancer	3.6e-05	0.000361	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CALR—esophageal cancer	3.59e-05	0.00036	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ALDH2—esophageal cancer	3.57e-05	0.000358	CbGpPWpGaD
Zoledronate—ABCC1—Disease—FBXW7—esophageal cancer	3.47e-05	0.000348	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTGS2—esophageal cancer	3.42e-05	0.000342	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GSTT1—esophageal cancer	3.39e-05	0.00034	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CYP2A6—esophageal cancer	3.36e-05	0.000336	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.34e-05	0.000335	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTGS2—esophageal cancer	3.29e-05	0.00033	CbGpPWpGaD
Zoledronate—CA14—Metabolism—EP300—esophageal cancer	3.25e-05	0.000326	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ENO1—esophageal cancer	3.18e-05	0.000319	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTGS1—esophageal cancer	3.18e-05	0.000319	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.18e-05	0.000319	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PSME2—esophageal cancer	3.13e-05	0.000314	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PSME1—esophageal cancer	3.13e-05	0.000314	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CREBBP—esophageal cancer	3.08e-05	0.000308	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—EP300—esophageal cancer	2.84e-05	0.000285	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TGFBR2—esophageal cancer	2.81e-05	0.000282	CbGpPWpGaD
Zoledronate—CA2—Metabolism—NOS3—esophageal cancer	2.75e-05	0.000276	CbGpPWpGaD
Zoledronate—CA12—Metabolism—EP300—esophageal cancer	2.74e-05	0.000275	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.74e-05	0.000274	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CYP1B1—esophageal cancer	2.7e-05	0.000271	CbGpPWpGaD
Zoledronate—ABCC1—Disease—SMAD4—esophageal cancer	2.66e-05	0.000267	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CYP19A1—esophageal cancer	2.54e-05	0.000255	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTGS2—esophageal cancer	2.52e-05	0.000252	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PIK3CA—esophageal cancer	2.4e-05	0.000241	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—HMOX1—esophageal cancer	2.32e-05	0.000233	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.28e-05	0.000228	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ABCB1—esophageal cancer	2.23e-05	0.000223	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HIF1A—esophageal cancer	2.18e-05	0.000218	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PIK3CA—esophageal cancer	2.1e-05	0.000211	CbGpPWpGaD
Zoledronate—CA2—Metabolism—EP300—esophageal cancer	2.09e-05	0.00021	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PIK3CA—esophageal cancer	2.03e-05	0.000203	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NOS2—esophageal cancer	1.98e-05	0.000198	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NOTCH1—esophageal cancer	1.96e-05	0.000196	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CREBBP—esophageal cancer	1.78e-05	0.000178	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.68e-05	0.000169	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NOS3—esophageal cancer	1.59e-05	0.000159	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PIK3CA—esophageal cancer	1.55e-05	0.000155	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CREBBP—esophageal cancer	1.49e-05	0.000149	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ERBB2—esophageal cancer	1.49e-05	0.000149	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PTGS2—esophageal cancer	1.46e-05	0.000146	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NOS3—esophageal cancer	1.33e-05	0.000134	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CDKN1A—esophageal cancer	1.27e-05	0.000127	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTGS2—esophageal cancer	1.22e-05	0.000122	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EP300—esophageal cancer	1.21e-05	0.000121	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MYC—esophageal cancer	1.05e-05	0.000106	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EGFR—esophageal cancer	1.03e-05	0.000103	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—EP300—esophageal cancer	1.01e-05	0.000102	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PIK3CA—esophageal cancer	8.96e-06	8.97e-05	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PIK3CA—esophageal cancer	7.5e-06	7.52e-05	CbGpPWpGaD
